Biogen Inc. (BIIB)

Market Cap	21.34B
Revenue (ttm)	9.61B
Net Income (ttm)	1.62B
Shares Out	145.72M
EPS (ttm)	11.06
PE Ratio	13.24
Forward PE	9.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,424,847
Open	145.64
Previous Close	147.39
Day's Range	145.07 - 147.85
52-Week Range	145.07 - 268.30
Beta	-0.08
Analysts	Buy
Price Target	248.00 (+69.32%)
Earnings Date	Feb 11, 2025

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Employees: 7,570
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB
• Website: https://www.biogen.com

Financial Performance

In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.

Analyst Forecast

According to 26 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $248.0, which is an increase of 69.32% from the latest price.

Price Target

$248.0

(69.32% upside)

Analyst Consensus: Buy